An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.
DLBCL
diffuse large B‐cell lymphoma
gene expression
immunochemotherapy
prognosis
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
20
01
2022
revised:
11
04
2022
accepted:
12
04
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Diffuse large B-cell lymphoma (DLBCL), the most frequent non-Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of
Identifiants
pubmed: 36051055
doi: 10.1002/jha2.457
pii: JHA2457
pmc: PMC9422037
doi:
Types de publication
Journal Article
Langues
eng
Pagination
722-733Informations de copyright
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
M.A.P. declares having received lecture fees and advisory board fees from Millennium/Takeda, Jansen, NanoString, Kyowa Kirin, Gilead, and Celgene.The authors declare that they have no significant relationships with, or financial interests, in any commercial companies pertaining to this article.
Références
Eur J Haematol. 2020 Apr;104(4):336-343
pubmed: 31944390
Blood. 2011 Jun 30;117(26):7070-8
pubmed: 21536860
Leukemia. 2012 Sep;26(9):2103-13
pubmed: 22437443
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
pubmed: 18765795
Lancet Oncol. 2019 May;20(5):649-662
pubmed: 30948276
Blood Adv. 2019 Jul 9;3(13):2013-2021
pubmed: 31285189
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Clin Cancer Res. 2011 Dec 15;17(24):7785-95
pubmed: 21933893
Haematologica. 2020 Feb 13;105(11):2667-2670
pubmed: 33131258
J Clin Oncol. 2016 Nov 20;34(33):4015-4022
pubmed: 28199143
Lancet Oncol. 2017 Aug;18(8):1076-1088
pubmed: 28668386
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Am J Hematol. 2020 Apr;95(4):435-445
pubmed: 32072672
J Clin Oncol. 2019 Jan 20;37(3):202-212
pubmed: 30523719
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Blood. 2008 Oct 15;112(8):3425-33
pubmed: 18544678
Hematol Oncol Clin North Am. 2016 Dec;30(6):1163-1177
pubmed: 27888873
Blood Cancer J. 2019 May 16;9(6):48
pubmed: 31097684
Future Oncol. 2016 Jul;12(13):1553-63
pubmed: 27089170
Hum Pathol. 2016 Aug;54:17-24
pubmed: 27045512
Blood. 2013 May 16;121(20):4021-31; quiz 4250
pubmed: 23449635
Blood. 2013 Apr 4;121(14):2715-24
pubmed: 23343832
Mod Pathol. 2012 Jul;25(7):968-82
pubmed: 22538516
Ann Oncol. 2021 Nov;32(11):1400-1409
pubmed: 34438040
Blood. 2013 Mar 21;121(12):2253-63
pubmed: 23335369
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Expert Rev Hematol. 2019 Dec;12(12):1095-1105
pubmed: 31592693
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
J Clin Oncol. 2019 Dec 10;37(35):3359-3368
pubmed: 31498031
Oncotarget. 2017 Jul 4;8(27):44960-44975
pubmed: 28402953
Clin Cancer Res. 2009 Sep 1;15(17):5494-502
pubmed: 19706817
J Clin Oncol. 2011 Jan 10;29(2):200-7
pubmed: 21135273
Oncotarget. 2018 Aug 17;9(64):32383-32399
pubmed: 30190794
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
J Clin Oncol. 2017 Aug 1;35(22):2515-2526
pubmed: 28525305
Blood. 2011 May 5;117(18):4836-43
pubmed: 21441466
J Clin Oncol. 2015 Sep 10;33(26):2848-56
pubmed: 26240231
Haematologica. 2021 Sep 01;106(9):2405-2416
pubmed: 32817282
Blood. 2018 May 3;131(18):2060-2064
pubmed: 29475959
Clin Cancer Res. 2014 May 1;20(9):2338-49
pubmed: 24583797
Am J Pathol. 2004 Feb;164(2):613-22
pubmed: 14742266
Mol Cancer Res. 2021 Feb;19(2):249-260
pubmed: 33154093
Ann Oncol. 2018 Dec 1;29(12):2363-2370
pubmed: 30307529
J Clin Oncol. 2012 Oct 1;30(28):3452-9
pubmed: 22851565
Blood. 2016 May 5;127(18):2182-8
pubmed: 26834242
Am J Hematol. 2020 Jan;95(1):57-67
pubmed: 31659781
J Clin Oncol. 1998 May;16(5):1931-9
pubmed: 9586912
J Clin Oncol. 2019 Jan 20;37(3):190-201
pubmed: 30523716
Ann Oncol. 2008 Nov;19(11):1921-6
pubmed: 18573805
Blood. 2011 Aug 4;118(5):1350-8
pubmed: 21670469
Oncotarget. 2016 Apr 5;7(14):18036-49
pubmed: 26910115
Blood. 2008 Oct 15;112(8):3088-98
pubmed: 18559976
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Oncotarget. 2015 Mar 20;6(8):5615-33
pubmed: 25760242
J Clin Oncol. 2019 May 20;37(15):1285-1295
pubmed: 30901302